Elderly breast cancer study pulled before it began
NCT ID NCT05664893
First seen Apr 20, 2026 · Last updated May 21, 2026 · Updated 4 times
Summary
This study aimed to test the safety and effectiveness of adding the drug ribociclib to standard hormone therapy and radiation for women aged 70 and older with a certain type of breast cancer. The participants would have been newly diagnosed and unable or unwilling to have surgery. However, the study was withdrawn before any patients were enrolled, so no results are available.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for HER2 NEGATIVE BREAST CANCER NOT IMMEDIATELY OPERATED are added.
Genom att skicka in godkänner du våra Användarvillkor
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
Genom att skicka in godkänner du våra Användarvillkor
Locations
-
Centre Antoine Lacassagne
Nice, 06189, France
Conditions
Explore the condition pages connected to this study.